Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.00
CELG's Cash to Debt is ranked higher than
56% of the 1256 Companies
in the Global Biotechnology industry.

( Industry Median: 47.96 vs. CELG: 1.00 )
CELG' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: 1

Equity to Asset 0.35
CELG's Equity to Asset is ranked higher than
57% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CELG: 0.35 )
CELG' s 10-Year Equity to Asset Range
Min: -0.68   Max: 0.92
Current: 0.35

-0.68
0.92
Interest Coverage 19.75
CELG's Interest Coverage is ranked higher than
54% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CELG: 19.75 )
CELG' s 10-Year Interest Coverage Range
Min: 4.47   Max: 428.04
Current: 19.75

4.47
428.04
F-Score: 7
Z-Score: 7.47
M-Score: -2.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 28.51
CELG's Operating margin (%) is ranked higher than
95% of the 1033 Companies
in the Global Biotechnology industry.

( Industry Median: -76.30 vs. CELG: 28.51 )
CELG' s 10-Year Operating margin (%) Range
Min: -2309.09   Max: 31.71
Current: 28.51

-2309.09
31.71
Net-margin (%) 21.80
CELG's Net-margin (%) is ranked higher than
94% of the 1033 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. CELG: 21.80 )
CELG' s 10-Year Net-margin (%) Range
Min: -2309.09   Max: 28.88
Current: 21.8

-2309.09
28.88
ROE (%) 30.10
CELG's ROE (%) is ranked higher than
97% of the 1151 Companies
in the Global Biotechnology industry.

( Industry Median: -34.30 vs. CELG: 30.10 )
CELG' s 10-Year ROE (%) Range
Min: -425.42   Max: 25.99
Current: 30.1

-425.42
25.99
ROA (%) 11.16
CELG's ROA (%) is ranked higher than
94% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -26.94 vs. CELG: 11.16 )
CELG' s 10-Year ROA (%) Range
Min: -166.78   Max: 15.8
Current: 11.16

-166.78
15.8
ROC (Joel Greenblatt) (%) 197.96
CELG's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 1234 Companies
in the Global Biotechnology industry.

( Industry Median: -394.00 vs. CELG: 197.96 )
CELG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1378.72   Max: 191.79
Current: 197.96

-1378.72
191.79
Revenue Growth (3Y)(%) 25.10
CELG's Revenue Growth (3Y)(%) is ranked higher than
91% of the 699 Companies
in the Global Biotechnology industry.

( Industry Median: -1.10 vs. CELG: 25.10 )
CELG' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 166.8
Current: 25.1

0
166.8
EBITDA Growth (3Y)(%) 21.90
CELG's EBITDA Growth (3Y)(%) is ranked higher than
91% of the 699 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. CELG: 21.90 )
CELG' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 75.6
Current: 21.9

0
75.6
EPS Growth (3Y)(%) 21.40
CELG's EPS Growth (3Y)(%) is ranked higher than
90% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. CELG: 21.40 )
CELG' s 10-Year EPS Growth (3Y)(%) Range
Min: -63.2   Max: 118.1
Current: 21.4

-63.2
118.1
» CELG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CELG Guru Trades in Q4 2013

Ray Dalio 6,700 sh (New)
Chuck Royce 900 sh (New)
Mario Gabelli 11,170 sh (+6.69%)
Ronald Muhlenkamp 147,425 sh (+2.87%)
John Keeley 1,320 sh (unchged)
Pioneer Investments 1,537,450 sh (-0.18%)
RS Investment Management 42,330 sh (-11.3%)
Ken Fisher 2,206 sh (-11.41%)
Jim Simons 1,405,469 sh (-15.72%)
Jeremy Grantham 86,922 sh (-36.84%)
Paul Tudor Jones 2,402 sh (-41.41%)
Louis Moore Bacon 5,000 sh (-75%)
Steven Cohen 18,867 sh (-77.3%)
» More
Q1 2014

CELG Guru Trades in Q1 2014

John Burbank 1,670 sh (New)
Ken Fisher 37,321 sh (+1591.8%)
Ray Dalio 71,200 sh (+962.69%)
Louis Moore Bacon 42,614 sh (+752.28%)
Steven Cohen 71,089 sh (+276.79%)
Paul Tudor Jones 6,686 sh (+178.35%)
Jim Simons 1,606,830 sh (+14.33%)
Ronald Muhlenkamp 149,325 sh (+1.29%)
Pioneer Investments 1,552,050 sh (+0.95%)
John Keeley Sold Out
Mario Gabelli 10,770 sh (-3.58%)
RS Investment Management 40,572 sh (-4.15%)
Chuck Royce 600 sh (-33.33%)
Jeremy Grantham 34,100 sh (-60.77%)
» More
Q2 2014

CELG Guru Trades in Q2 2014

Stanley Druckenmiller 276,000 sh (New)
George Soros 688,000 sh (New)
Joel Greenblatt 63,980 sh (New)
Ken Fisher 131,064 sh (+75.59%)
Mario Gabelli 23,120 sh (+7.34%)
Steven Cohen 204,200 sh (unchged)
Chuck Royce Sold Out
Paul Tudor Jones Sold Out
Louis Moore Bacon Sold Out
John Burbank Sold Out
Ray Dalio Sold Out
Pioneer Investments 3,052,643 sh (-1.66%)
RS Investment Management 75,104 sh (-7.44%)
Jeremy Grantham 50,000 sh (-26.69%)
Ronald Muhlenkamp 144,140 sh (-51.74%)
Jim Simons 495,900 sh (-84.57%)
» More
Q3 2014

CELG Guru Trades in Q3 2014

Louis Moore Bacon 55,000 sh (New)
John Hussman 25,000 sh (New)
Stanley Druckenmiller 560,600 sh (+103.12%)
Ken Fisher 232,137 sh (+77.12%)
RS Investment Management 86,904 sh (+15.71%)
Mario Gabelli 25,760 sh (+11.42%)
Ronald Muhlenkamp 146,940 sh (+1.94%)
Pioneer Investments 3,080,374 sh (+0.91%)
Steven Cohen Sold Out
George Soros Sold Out
Joel Greenblatt Sold Out
Jeremy Grantham Sold Out
Jim Simons 30,400 sh (-93.87%)
» More
» Details

Insider Trades

Latest Guru Trades with CELG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-09-30 Sold Out 0.45%$83.13 - $96.21 $ 123.8937%0
John Hussman 2014-09-30 New Buy0.2%$83.13 - $96.21 $ 123.8937%25000
Joel Greenblatt 2014-09-30 Sold Out 0.07%$83.13 - $96.21 $ 123.8937%0
Ken Fisher 2014-09-30 Add 77.12%0.02%$83.13 - $96.21 $ 123.8937%232137
Ronald Muhlenkamp 2014-06-30 Reduce -51.74%1.91%$68.45 - $86.8 $ 123.8963%144140
George Soros 2014-06-30 New Buy0.45%$68.45 - $86.8 $ 123.8963%688000
Ray Dalio 2014-06-30 Sold Out 0.08%$68.45 - $86.8 $ 123.8963%0
Joel Greenblatt 2014-06-30 New Buy0.07%$68.45 - $86.8 $ 123.8963%63980
John Burbank 2014-06-30 Sold Out 0.01%$68.45 - $86.8 $ 123.8963%0
Ken Fisher 2014-06-30 Add 75.59%0.01%$68.45 - $86.8 $ 123.8963%131064
Ray Dalio 2014-03-31 Add 962.69%0.07%$69.65 - $85.97 $ 123.8956%142400
John Burbank 2014-03-31 New Buy0.01%$69.65 - $85.97 $ 123.8956%3340
Ken Fisher 2014-03-31 Add 1591.8%0.01%$69.65 - $85.97 $ 123.8956%74642
John Keeley 2014-03-31 Sold Out $69.65 - $85.97 $ 123.8956%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 64.90
CELG's P/E(ttm) is ranked higher than
91% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 64.90 )
CELG' s 10-Year P/E(ttm) Range
Min: 17.91   Max: 618.59
Current: 64.9

17.91
618.59
Forward P/E 18.80
CELG's Forward P/E is ranked higher than
96% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 18.80 )
N/A
PE(NRI) 64.90
CELG's PE(NRI) is ranked higher than
91% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 64.90 )
CELG' s 10-Year PE(NRI) Range
Min: 17.81   Max: 482.5
Current: 64.9

17.81
482.5
P/B 17.18
CELG's P/B is ranked higher than
61% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 6.38 vs. CELG: 17.18 )
CELG' s 10-Year P/B Range
Min: 4.02   Max: 23.45
Current: 17.18

4.02
23.45
P/S 14.21
CELG's P/S is ranked higher than
79% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 28.95 vs. CELG: 14.21 )
CELG' s 10-Year P/S Range
Min: 5.37   Max: 28.35
Current: 14.21

5.37
28.35
PFCF 43.78
CELG's PFCF is ranked higher than
95% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 43.78 )
CELG' s 10-Year PFCF Range
Min: 14.96   Max: 2925.5
Current: 43.78

14.96
2925.5
POCF 41.30
CELG's POCF is ranked higher than
92% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 41.30 )
CELG' s 10-Year POCF Range
Min: 13.82   Max: 937.83
Current: 41.3

13.82
937.83
EV-to-EBIT 47.26
CELG's EV-to-EBIT is ranked higher than
91% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 47.26 )
CELG' s 10-Year EV-to-EBIT Range
Min: -26.2   Max: 820.6
Current: 47.26

-26.2
820.6
PEG 2.92
CELG's PEG is ranked higher than
97% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 2.92 )
CELG' s 10-Year PEG Range
Min: 1.38   Max: 3.19
Current: 2.92

1.38
3.19
Shiller P/E 90.03
CELG's Shiller P/E is ranked higher than
95% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 90.03 )
CELG' s 10-Year Shiller P/E Range
Min: 57.04   Max: 2211
Current: 90.03

57.04
2211
Current Ratio 6.32
CELG's Current Ratio is ranked higher than
79% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. CELG: 6.32 )
CELG' s 10-Year Current Ratio Range
Min: 1.35   Max: 44.53
Current: 6.32

1.35
44.53
Quick Ratio 6.06
CELG's Quick Ratio is ranked higher than
79% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. CELG: 6.06 )
CELG' s 10-Year Quick Ratio Range
Min: 1.13   Max: 44.15
Current: 6.06

1.13
44.15
Days Inventory 337.01
CELG's Days Inventory is ranked higher than
78% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 337.01 )
CELG' s 10-Year Days Inventory Range
Min: 49.98   Max: 584
Current: 337.01

49.98
584
Days Sales Outstanding 53.11
CELG's Days Sales Outstanding is ranked higher than
85% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 115.94 vs. CELG: 53.11 )
CELG' s 10-Year Days Sales Outstanding Range
Min: 42.33   Max: 464.55
Current: 53.11

42.33
464.55

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 3.82
CELG's Price/DCF (Projected) is ranked higher than
94% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 3.82 )
CELG' s 10-Year Price/DCF (Projected) Range
Min: 1.66   Max: 122.67
Current: 3.82

1.66
122.67
Price/Median PS Value 1.31
CELG's Price/Median PS Value is ranked higher than
80% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 2.32 vs. CELG: 1.31 )
CELG' s 10-Year Price/Median PS Value Range
Min: 0.52   Max: 7.59
Current: 1.31

0.52
7.59
Price/Peter Lynch Fair Value 3.19
CELG's Price/Peter Lynch Fair Value is ranked higher than
98% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 3.19 )
CELG' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.36   Max: 5.1
Current: 3.19

0.36
5.1
Earnings Yield (Greenblatt) 2.10
CELG's Earnings Yield (Greenblatt) is ranked higher than
91% of the 1236 Companies
in the Global Biotechnology industry.

( Industry Median: -5.70 vs. CELG: 2.10 )
CELG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 6.6
Current: 2.1

0.1
6.6
Forward Rate of Return (Yacktman) 21.96
CELG's Forward Rate of Return (Yacktman) is ranked higher than
86% of the 163 Companies
in the Global Biotechnology industry.

( Industry Median: 14.57 vs. CELG: 21.96 )
CELG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.5   Max: 34.8
Current: 21.96

-0.5
34.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CMXHY » details
Traded in other countries:CG3.Germany, CELG.Mexico, CELG.Switzerland,
Celgene Corp is incorporated in Delaware. The Company is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of new therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in new research and development designed to bring new therapies to market and we are involved in research in several scientific areas that may deliver proprietary next-generation therapies, targeting areas including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The Company' commercial stage products include REVLIMID(r), VIDAZA(r), ABRAXANE(r), POMALYST(r)/IMNOVID(r), THALOMID(r) (inclusive of Thalidomide CelgeneTM), ISTODAX(r) and azacitidine for injection (generic version of VIDAZA(r)). The Company faces competition from Amgen, AstraZeneca, Bristol-Myers-Squibb, Eisai, Gilead, Johnson & Johnson, Novartis, Pharmacyclics, Roche/Genentech, Sanofi and Takeda, AbbVie, Amgen, Biogen Idec, Eisai, Johnson & Johnson, Merck, Pfizer and UCB S.A. Regulation by governmental authorities in the United States and other countries is a significant factor in the manufacture and marketing of pharmaceuticals and in its ongoing research and development activities.
» More Articles for CELG

Headlines

Articles On GuruFocus.com
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Nov 18 2014 
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Coun Nov 17 2014 
Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 
Weekly 52-Week Highs Highlight: ALL, SRE, CLX, CELG Oct 05 2014 
Ken Fisher's Top Increases of the First Quarter Apr 22 2014 
David Winters' 2013 Letter to Wintergreen Fund Shareholders Mar 05 2014 
You Can No Longer Ignore Biotech Feb 07 2014 
Trying to Beat the Market Is a Fool’s Errand Oct 17 2013 
Insiders Are Buying Idera Pharmaceuticals Sep 19 2013 

More From Our Partners
Novartis' Psoriasis Drug Cosentyx Gets FDA Approval - Analyst Blog Jan 22 2015 - ZACKS

More From Other Websites
7:19 am Celgene receives positive chmp opinion for ABRAXANE for first-line treatment of patients... Jan 25 2015
Apple, Facebook Lead Top IBD 50 Earnings This Week Jan 24 2015
Cramer: Overwhelmed with earnings next week Jan 23 2015
Celgene Receives Positive CHMP Opinion for ABRAXANE® for First-Line Treatment of Patients with... Jan 23 2015
Novartis' Psoriasis Drug Cosentyx Gets FDA Approval - Analyst Blog Jan 22 2015
Keryx to Raise $110 Million Through Issuance of Shares - Analyst Blog Jan 22 2015
Arena Pharmaceuticals to Raise Fund Via Share Issuance - Analyst Blog Jan 22 2015
Celgene to Use Zymeworks' Azymetric Platform for New Drugs - Analyst Blog Jan 22 2015
The Zacks Analyst Blog Highlights: AbbVie, Gilead and Celgene - Press Releases Jan 22 2015
Alnylam to Raise $450 Million Through Issuance of Shares - Analyst Blog Jan 21 2015
Affymetrix Hits 52-Week High on Strong Top-Line Growth - Analyst Blog Jan 21 2015
Celgene, Biotech's Ace Dealmaker, Bets On Canada's Zymeworks Jan 21 2015
Supernus Downgraded as Lead Drugs Face Patent Challenges - Analyst Blog Jan 20 2015
J&J Beats on Q4 Earnings, Revenues Hit by Currency - Analyst Blog Jan 20 2015
Major U.S. benchmarks challenge last-ditch support Jan 20 2015
Cramer's Stop Trading: Biotech hangover Jan 20 2015
Celgene Up as Otezla Gains EU Approval for Two Indications - Analyst Blog Jan 19 2015
EU Oks new Celgene pill for psoriasis, psoriatic arthritis Jan 16 2015
EU Oks new Celgene pill for psoriasis, psoriatic arthritis Jan 16 2015
Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients... Jan 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK